Allied Market Research published a report on the consumer healthcare market, which offers industry dynamics, including growth drivers, opportunities, and challenges. This report provides a competitive landscape of the sector. The global industry was valued at $280.1 billion in 2022 and is projected to reach $574.4 billion by 2032, growing at a CAGR of 7.5% from 2023 to 2032.
Consumer healthcare majorly focuses on over the counter (OTC) drugs that are sold to the customer without prescription from a healthcare professional. The consumer healthcare sector is driven by a shift in trend for self-medication. In addition, rise in aging population who is prone to diseases and shift among consumers toward OTC drugs foster the growth of the market. Moreover, developments in healthcare infrastructure and approvals from government for preventive medicine and wellness boost the growth of the consumer healthcare market.
However, stringent government regulations limit the growth of the market. Moreover, availability of counterfeit pharmaceutical drugs also restrains the market growth. Nevertheless, research and development in the OTC sector is projected to contribute toward the demand for consumer healthcare products in the market.
Important questions
What are the key factors driving the growth of this industry?
Which companies are the leading players in the domain?
Which distribution channel leads the consumer healthcare market?
What are the factors that restrain the growth of the sector?
What is the dominating segment based on product?
On the basis of region, North America is projected to witness growth due to rise in adoption of over-the-counter medication. In addition, developments in healthcare infrastructure and surge in awareness about dietary supplements across the region also foster the adoption of consumer healthcare products in North America.
The Asia-Pacific region is anticipated to experience growth due to increase in disposable income and surge in per capita spending. There is an increase in the aging population, who are prone to developing cardiovascular or other diseases, which fosters the demand for OTC drugs in the Asia-Pacific region. In addition, rise in awareness of patient centric treatment across the region fosters the demand for consumer healthcare products in Asia-Pacific.
Key benefits for stakeholders
The report offers an in-depth analysis of market segments, prevailing trends, forecasts, and dynamics within the global consumer healthcare market from 2024 to 2033, with a primary focus on identifying business opportunities. The research report analyzes the market by utilizing tools such as Porter’s five forces analysis, value chain analysis, opportunity map analysis, drivers & restraints impact analysis, and the market attractiveness index to provide a well-studied market assessment.
In addition, the research examines key players in the global consumer healthcare market, offering insights into their company profiles, market strategies, and supply-demand dynamics. It evaluates the competitive landscape, helping stakeholders identify potential partners or rivals.
List of Key players
Major key players operating in the global consumer healthcare market include:
BASF SE
Teva Pharmaceutical Industries Ltd.
Johnson & Johnson
Boehringer Ingelheim GmbH
Abbott Laboratories
Pfizer Inc.
Sanofi
Amway
Bayer AG
GlaxoSmithKline plc
These players have adopted different strategies, such as agreement, acquisition, branding, product launch, and product approval to sustain their foothold and improve the product portfolio of the consumer healthcare market.
To sum up
The AMR report offers a detailed study of the industry, including a comprehensive competitive landscape. It further highlights emerging trends, key growth drivers, and potential opportunities that empower industry leaders and stakeholders to make informed strategic decisions. The report serves as a valuable resource for understanding changes in the domain, mitigating risks, and supporting long-term business growth in an increasingly competitive environment by offering in-depth insights.
0 Comments